1. Before 1982, the medical community always believed that it was emotional, nervous tension, work stress, etc. that caused stomach problems. Barry Marshall and Robin Warren won the Nobel Prize in Medicine in 2005, subverting people's “common sense” about stomach problems and changing the way people think they are caused by stress and other factors (diseases such as stomach ulcers).

2. Currently, Hp infection has been recognized as an important cause of chronic gastritis and gastroduodenal ulcers, but the Hp chemical treatment plan has certain adverse effects, which are easy to recur after discontinuation of the drug, and drug-resistant strains have gradually increased, which greatly limits the clinical application of the “triple” therapy currently commonly used. Vaccines are expected to be one of the most effective and promising ways to prevent and cure Hp infections.

3. Under the leadership of its chief scientist, Professor Zou Quanming, Chongqing Kangwei, a subsidiary of Yueyang Xing, succeeded in using the unique intramolecular adjuvant Helicobacter pylori vaccine. In 2007, the China Pharmaceutical and Biological Products Inspection Institute issued Central Inspection Letter [2007] No. 187. It marks the end of the Yueyang Xingchang Hp vaccine phase III clinical trial. It was the first in the world to complete a clinical Hp vaccine product.

4. There is broad market demand for the Hp vaccine, but since we analyze the demand for future product markets, we used a scenario analysis method and determined the company's likely market size under both optimistic and conservative conditions.

5. Although we have warned investors of sufficient risks, after all, the Hp vaccine is the world's first vaccine product, and its market is huge, and these all require us to pay full attention to this product. Although we have not given the company's investment rating yet, we are actively following and recommend investors to pay active attention.